186 related articles for article (PubMed ID: 10809436)
1. Long-term therapy for postrenal transplant erythrocytosis with ACE inhibitors: efficacy, safety and action mechanisms.
Montanaro D; Groupuzzo M; Boscutti G; Risaliti A; Bresadola F; Mioni G
Clin Nephrol; 2000 Apr; 53(4):suppl 47-51. PubMed ID: 10809436
[TBL] [Abstract][Full Text] [Related]
2. Effect of the angiotensin-converting enzyme inhibitor enalapril on post-transplant erythrocytosis.
Marubayashi S; Yamamoto H; Shibata S; Fudaba Y; Miyata Y; Fukuma K; Okada K; Hinoi T; Ikeda M; Maeda T; Oshiro Y; Dohi K
Hiroshima J Med Sci; 1998 Sep; 47(3):121-4. PubMed ID: 9810784
[TBL] [Abstract][Full Text] [Related]
3. Ramipril in post-renal transplant erythrocytosis.
Esposito R; Giammarino A; De Blasio A; Martinelli V; Cirillo F; Scopacasa F; Federico S; Russo D
J Nephrol; 2007; 20(1):57-62. PubMed ID: 17347974
[TBL] [Abstract][Full Text] [Related]
4. Posttransplant erythrocytosis in renal transplant recipients at Jeddah Kidney Center, Kingdom of Saudi Arabia.
Basri N; Gendo MZ; Haider R; Abdullah KA; Hassan A; Shaheen FA
Exp Clin Transplant; 2007 Jun; 5(1):607-9. PubMed ID: 17617052
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-converting enzyme inhibitors after renal transplantation.
Bravo P; Felgueiras J; Santos C; Oliveira C; Ponce P
Transplant Proc; 2008 Apr; 40(3):740-2. PubMed ID: 18455003
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-converting enzyme inhibitor-induced anemia and treatment for erythrocytosis in renal transplant recipients.
Satoh S; Kaneko T; Seino K; Abe T; Omori S; Sugimura J; Fujioka T; Kubo T
Nihon Jinzo Gakkai Shi; 1995 Jun; 37(6):343-7. PubMed ID: 7666600
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-converting enzyme inhibition in the treatment of renal transplant erythrocytosis. Clinical experience and observation of mechanism.
Danovitch GM; Jamgotchian NJ; Eggena PH; Paul W; Barrett JD; Wilkinson A; Lee DB
Transplantation; 1995 Jul; 60(2):132-7. PubMed ID: 7624954
[TBL] [Abstract][Full Text] [Related]
8. Influence of angiotensin-converting enzyme polymorphism gene, IGF-1, and other factors in the response rate of hematocrit to enalapril treatment in patients with posttransplant erythrocytosis.
Jimeno L; Rodado R; Barrios Y; Campos M; Llorente S; Nicolas F; Minguela A
Transplant Proc; 2005 Mar; 37(2):1012-3. PubMed ID: 15848608
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of captopril on posttransplant erythrocytosis. Long-term follow-up.
Torregrosa JV; Campistol JM; Montesinos M; Rogada AG; Oppenheimer F; Andreu J
Transplantation; 1994 Aug; 58(3):311-4. PubMed ID: 8053053
[TBL] [Abstract][Full Text] [Related]
10. Factors predisposing to post-renal transplant erythrocytosis. A prospective matched-pair control study.
Kessler M; Hestin D; Mayeux D; Mertes PM; Renoult E
Clin Nephrol; 1996 Feb; 45(2):83-9. PubMed ID: 8846535
[TBL] [Abstract][Full Text] [Related]
11. Treatment of postrenal transplant erythrocytosis. Long-term efficacy and safety of angiotensin-converting enzyme inhibitors.
MacGregor MS; Rowe PA; Watson MA; Rodger RS; Junor BJ; Briggs JD
Nephron; 1996; 74(3):517-21. PubMed ID: 8938674
[TBL] [Abstract][Full Text] [Related]
12. Correction of posttransplant erythrocytosis with enalapril.
Rell K; Koziak K; Jarzyo I; Lao M; Gaciong Z
Transplantation; 1994 Apr; 57(7):1059-63. PubMed ID: 8165703
[TBL] [Abstract][Full Text] [Related]
13. ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy.
Stigant CE; Cohen J; Vivera M; Zaltzman JS
Am J Kidney Dis; 2000 Jan; 35(1):58-63. PubMed ID: 10620545
[TBL] [Abstract][Full Text] [Related]
14. Effects of losartan or enalapril on hemoglobin, circulating erythropoietin, and insulin-like growth factor-1 in patients with and without posttransplant erythrocytosis.
Wang AY; Yu AW; Lam CW; Yu LM; Li PK; Goh J; Lui SF
Am J Kidney Dis; 2002 Mar; 39(3):600-8. PubMed ID: 11877580
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients.
Suwelack B; Kobelt V; Erfmann M; Hausberg M; Gerhardt U; Rahn KH; Hohage H
Transpl Int; 2003 May; 16(5):313-20. PubMed ID: 12759722
[TBL] [Abstract][Full Text] [Related]
16. Posttransplant erythrocytosis: a model for the investigation of the pharmacological control of renal erythropoietin production?
Gleiter CH
Int J Clin Pharmacol Ther; 1996 Nov; 34(11):489-92. PubMed ID: 8937931
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of post-transplant erythrocytosis: comparison of lisinopril and theophylline].
D'Amelio A; Bonucchi D; Patruno P; Ballestri M; Mastrangelo F
Minerva Cardioangiol; 1997 Nov; 45(11):567-72. PubMed ID: 9549290
[TBL] [Abstract][Full Text] [Related]
18. Role of ACE inhibitors in the treatment of erythrocytosis in patients with renal allograft.
Pisani F; Tisone G; Alciati E; Vennarecci G; Pieragostini E; Casciani CU
Transplant Proc; 1994 Oct; 26(5):2602-3. PubMed ID: 7940809
[No Abstract] [Full Text] [Related]
19. Influence of angiotensin I-converting enzyme polymorphism on development of post-transplant erythrocytosis in renal graft recipients.
Kedzierska K; Kabat-Koperska J; Safranow K; Domański M; Gołembiewska E; Bober J; Bohatyrewicz R; Ciechanowski K
Clin Transplant; 2008; 22(2):156-61. PubMed ID: 18339134
[TBL] [Abstract][Full Text] [Related]
20. Renal allograft protection with early angiotensin-converting enzyme inhibitors administration.
Montanaro D; Gropuzzo M; Tulissi P; Boscutti G; Mioni R; Risaliti A; Baccarani U; Adani GL; Sainz M; Bresadola F; Mioni G
Transplant Proc; 2004 Apr; 36(3):692-4. PubMed ID: 15110633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
